How to Use the
Helixera Research Library
A practical guide to navigating compound data, designing research protocols, understanding evidence levels, and getting the most out of the Helixera documentation.
Start Here
The Helixera Research Library contains detailed compound overview pages for every product we carry. Each page covers the same structure: mechanism of action, key research areas, typical protocol parameters, compound comparisons, safety profile, and FAQ. This consistency makes it easy to compare compounds across categories.
If you're new to a category, the category landing pages provide a curated overview of all compounds and how they relate to each other — a better starting point than jumping directly to individual compound pages.
Understanding Evidence Levels
Not all compounds in the library have the same depth of evidence. Here's how to read the evidence descriptors used across the research pages:
FDA Approved
The compound has completed Phase 3 clinical trials and received FDA marketing approval for at least one indication. Semaglutide, tirzepatide, tesamorelin, HCG, PT-141, and Melanotan I fall here. Note: we supply these for research use only, not their approved indications.
Phase 2/3 Clinical Data
Formal human clinical trials have been completed. The compound has human pharmacokinetic, safety, and efficacy data — but is not FDA approved. Retatrutide, MK-677, ARA-290 examples.
Approved Outside US / Russian Clinical
Compounds like Thymosin Alpha-1 (approved in 37+ countries) and Semax/Selank (clinical use in Russia) have substantial human data — but not from FDA-reviewed trials. Data quality varies; Russian-language literature may be limited in Western access.
Extensive Preclinical
Multiple published animal model studies across several research groups. BPC-157 (100+ studies), TB-500, GHK-Cu fall here. High-quality evidence for mechanism and animal model efficacy — but no formal human trials.
Early Preclinical
Initial published preclinical findings — often from a single research group. Compelling mechanistic rationale but limited replication. SLU-PP-332, BAM15, FOXO4-DRI are examples. Higher uncertainty; treat as hypothesis-generating.
Reading a Compound Overview Page
Each compound overview follows a consistent structure. Here's what each section is designed to tell you:
Protocol Design Principles
Helixera's research pages provide protocol reference data — not prescription protocols. When designing a research protocol, consider:
- Research objective first: Define exactly what you're measuring before selecting compounds. The compound should match the mechanism you're studying, not the other way around.
- Evidence level matters: Design protocols with appropriate uncertainty bounds based on the evidence level of the compound. Early preclinical data warrants wider dose ranges and more outcome monitoring than Phase 3-validated compounds.
- Half-life determines frequency: Dosing frequency must align with the compound's half-life to maintain appropriate concentrations. See the Peptide Guide for reference half-life data.
- Route affects outcome: For compounds with multiple studied routes (oral, SC, IV, topical), the route affects tissue distribution, bioavailability, and the specific effects observed. Match route to the research question.
- Controls are non-negotiable: Vehicle controls, sham controls, and positive controls — appropriate to your model — are essential for interpretable results with any research compound.
- Institutional compliance: Ensure all protocols comply with your institution's IACUC, IRB, or relevant ethics committee requirements before initiating any research.
Ready to find your compound?
Browse the full library with search and category filters.
Helixera Labs LLC · helixerapeptides.com · All products for laboratory research use only · Not for human or veterinary use · © 2026